ArticleFrontiers in oncology2022
A detection panel of novel methylated DNA markers for malignant pleural effusion.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Clinical value of combinedOncology reviews · 2026Pooled it
- Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta-analysis.Cancer cytopathology · 2025Pooled it
- Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.European journal of haematology · 2026Article
- A liquid biopsy-based multi-methylation marker panel for minimally invasive gastric cancer screening.Clinical epigenetics · 2026Article
- Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies.Molecular oncology · 2026Article
- Diagnostic efficacy and subgroup heterogeneity of SHOX2, RASSF1A, Septin9, and HOXA9 methylation in pleural effusion lymphoma.Clinical epigenetics · 2025Article
- Development and Validation of a Clinlabomics-Based Nomogram for Predicting the Prognosis of Small Cell Lung Cancer in China: A Multicenter, Retrospective Cohort Study.Cancer medicine · 2025Observational
- Diagnostic accuracy of SHOX-2 methylation for malignant pleural effusion: a systematic review and meta-analysis.Translational cancer research · 2025Article
- Detecting plasma SHOX2, HOXA9, SEPTIN9, and RASSF1A methylation and circulating cancer cells for cholangiocarcinoma clinical diagnosis and monitoring.World journal of gastrointestinal oncology · 2025Article
- Enhancing the precision of auxiliary diagnosis for lung cancer through use ofTranslational lung cancer research · 2025Article
- Diagnostic and prognostic value of polygene methylation detection in ascites.Frontiers in genetics · 2025Article
- Lung tumor discrimination by deep neural network model CanDo via DNA methylation in bronchial lavage.iScience · 2024Article
- Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.BMC cancer · 2024Article
- Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid.Scientific reports · 2024Article
- Cell-Free DNA Methylation Analysis as a Marker of Malignancy in Pleural Fluid.Research square · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytology remains the gold standard for the detection of malignant cells in pleural effusion. However, its sensitivity is limited. The aim of this study was to establish a novel panel of cancer-specific methylated genes for the differential diagnosis of malignant pleural effusion (MPE). Methods: A cohort of 100 cancer patients (68 lung cancer, 32 other malignant tumors) and 48 patients with benign disease presenting with pleural effusion was prospectively enrolled. Pleural effusion was evaluated by means of cytopathological investigation and DNA methylation of SHOX2, RASSF1A, SEPTIN9 and HOXA9 in the cellular fraction. DNA methylation in bisulfite-converted DNA was determined using quantitative methylation-specific real-time PCR (MS-PCR). Cytopathological and DNA methylation results were evaluated with regard to the final clinical diagnosis. Results: The LungMe Conclusion: OncoMe has potential for use as a biomarker for the detection of MPE, even not limited to lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.